MTN-039 was a Phase I study launched in late 2019 that was designed to evaluate the safety and acceptability of a fast-dissolving rectal insert containing the antiretroviral drugs tenofovir and elvitegravir, as well as the degree that each drug concentrates in rectal tissue. The study, the first ever of the tenofovir and elvitegravir insert used rectally, enrolled 23 participants at two sites in the U.S.
Fast-dissolving insert found safe, shows promise as method for preventing HIV through anal sex
21-February-2023
MTN-039 Backgrounder
12-December-2019
See also
MTN-039 Study Protocol